MRI improved LLM-based recurrence prediction after definitive cervical chemoradiotherapy
Multimodal LLM prediction reached an AUC of 0.79, but AI-generated MRI reports showed clinically important discordances requiring expert review.
Latest research
Search the archiveProton FLASH requires dedicated reassessment of shielding, activation and radiation safety
Five proton centres outline why conventional radiation protection workflows cannot simply be assumed adequate for ultra-high dose-rate FLASH research.
Proton STAR workflow proved technically feasible for refractory ventricular tachycardia
A preclinical proton STAR workflow achieved benchmark-level target coverage, OAR sparing and cardiac gating latency below 30 ms.
SBRT added to intermittent ADT delays biochemical progression in PSMA PET-only oligometastatic prostate cancer
In randomized i-STOP, adding SBRT to intermittent ADT reduced 3-year biochemical progression from 60% to 21% in PSMA PET-only oligometastatic prostate cancer. ADT re-initiation was also numerically less frequent, but not significantly.
20-fraction proton therapy is noninferior to 39 fractions for 3-year bowel outcomes in prostate cancer
In the randomized COMPPARE proton cohort, 60 Gy(RBE) in 20 fractions was noninferior to 78 Gy(RBE) in 39 fractions for 3-year bowel function, with similar grade 2+ GI toxicity and biochemical control.
Six months of ADT reduces metastases and prostate cancer mortality without improving overall survival after dose-escalated RT
Long-term NRG/RTOG 0815 shows that adding 6 months of ADT to dose-escalated RT reduces biochemical failure, metastases, and prostate cancer mortality, but still does not significantly improve overall survival.
Brachytherapy boost fails to improve biochemical control over 80 Gy EBRT in intermediate-risk prostate cancer
In phase III GETUG P05, brachytherapy boost did not improve 5-year biochemical control over dose-escalated EBRT to 80 Gy in intermediate-risk prostate cancer and increased mild-to-moderate urinary toxicity.
Darolutamide preserves erectile function but fails PSA noninferiority vs ADT with prostate RT
In INTREPID, replacing 6 months of ADT with darolutamide during RT preserved erectile function but failed the prespecified noninferiority endpoint for early PSA suppression. Longer-term oncologic outcomes remain pending
Four support needs may help children complete proton therapy without anaesthesia
Control, predictability, information and relational continuity emerged as key needs for making awake pediatric proton therapy more manageable.
RTT-led online adaptive radiotherapy maintained cervical target coverage in 33-minute sessions
Across 744 cervical oART fractions, RTT-led adaptation took a median 33 minutes while maintaining ≥95% target D98 in every fraction.
Target-volume model predicted HyTEC-based SRS prescriptions before plan generation
A model using target volume and HyTEC limits estimated automated SRS prescription doses with approximately 1.3% mean absolute error.
Proton reirradiation achieved durable survival with limited severe toxicity in recurrent pediatric ependymoma
After proton reirradiation for recurrent pediatric ependymoma, 5-year survival was 64% with one grade 3 radiation injury and no grade 4+ toxicity.
Higher minimum target dose improved local control after repeat spine SBRT
After repeat spine SBRT, 12-month local failure was 6% with Dmin ≥28 Gy EQD2 versus 36% below that level.
Comprehensive radiotherapy tracked with longer survival in recurrent glioblastoma leptomeningeal dissemination
In recurrent IDH-wildtype glioblastoma LMD, comprehensive RT and systemic therapy were independently associated with longer survival.
Four doses of nivolumab after SABR improve 6-year survival in early-stage NSCLC
In randomized phase II I-SABR, four doses of nivolumab added to SABR improved 6-year OS to 69% vs 55% and EFS to 55% vs 32%. The long-term signal is compelling, but OS was a secondary endpoint in a relatively small phase II trial.